Abstract:Objective: To detect the high mobility group A2 (HMGA2) expression in renal carcinoma, and to explore the relationship with clinicopathological features and its significance for prognosis. Methods: 50 renal carcinoma specimens, 50 corresponding adjacent normal kidney tissue samples, and 40 benign renal tumor specimens were used in this study. The expressions of HMGA2 mRNA and protein were detected by RT-PCR, Western blot and immunohistochemical assays, and its relationship with clinicopathological features and prognosis in the renal carcinoma patients was analyzed. Results: The RT-PCR results showed that the relative expression levels of HMGA2 mRNA in the renal carcinoma, benign renal tumor tissues, and adjacent normal renal tissues were 0.84±0.23, 0.19± 0.06 and 0.08±0.04, respectively, and the expression in renal carcinoma tissue was significantly higher than those of the other 2 groups (P<0.01). The Western blot results showed that the relative expression levels of HMGA2 protein in the renal carcinoma, benign renal tumor tissues, and adjacent normal renal tissues were 0.91±0.24, 0.12±0.04 and 0.03±0.01, respectively, and the expression in renal carcinoma tissue was significantly higher than those of the other 2 groups (P<0.01). Immunohistochemical results showed that the expression of HMGA2 protein exhibited brown and tan granular, which mainly distributed in the cell nuclei. Among the 50 cases of renal carcinoma, 34 cases exhibited positive expression, with a positive rate of 68.0%. Among the 40 cases of benign tumor tissues, 3 cases had positive expression, with a positive rate of 7.5%, while among the 50 cases of adjacent normal renal tissues, there was only 1 case exhibiting positive expression of HMGA2 protein, with a positive rate of 2.0%. The protein expression of HMGA2 was significantly higher in the renal carcinoma than in the benign tumors and normal renal tissues (P=0.004). There was no statistically significant difference in the association of HMGA2 protein expressions with age, sex, tumor size and histological type (P>0.05), while significant difference did exist in the association with different statuses of TNM staging and lymph node metastasis (P<0.05). The median time to progression (TTP) in 34 HMGA2 protein-positive patients was (22.36±1.48) months and that of 16 HMGA2 protein-negative patients was (34.55±1.87) months (P<0.05). Conclusions: HMGA2 plays an important role in the tumorigenesis and development of renal carcinoma, and may be used as an important predictor for estimating the prognosis of renal carcinoma. HMGA2 might become a new diagnostic and prognostic marker for renal carcinoma.

Prognostic Significance of HMGA1 Expression in Lung Cancer Based on Bioinformatics Analysis

Elevated Expression of HMGA1 Correlates with the Malignant Status and Prognosis of Non-Small Cell Lung Cancer

Overexpression Of Hmga2 Promotes Metastasis And Impacts Survival Of Advanced Colorectal Cancers

[Expression and Its Clinical Significance of HMGA2 in the Patients with Non-Small Cell Lung Cancer.].

HMGA1 As a Potential Prognostic and Therapeutic Biomarker in Breast Cancer

The Effect of HMGB1 on the Clinicopathological and Prognostic Features of Cervical Cancer.

HMGA2 Regulates Lung Cancer Proliferation and Metastasis

Comprehensive Bioinformatics Analysis to Identify the Gene HMMR Associated with Lung Adenocarcinoma Prognosis and Its Mechanism of Action in Multiple Cancers.

Pan-cancer Multi-omics Analysis Reveals HMGN1 as a Potential Prognostic and Immune Infiltration-associated Biomarker

Prognostic Value of HMGA2 in Human Cancers: A Meta-Analysis Based on Literatures and TCGA Datasets

Validating <i>HMMR</i> Expression and Its Prognostic Significance in Lung Adenocarcinoma Based on Data Mining and Bioinformatics Methods

Loss of LIMCH1 Predicts Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics

High Mobility Group Box Protein 1 Serves As a Potential Prognostic Marker of Lung Cancer and Promotes Its Invasion and Metastasis by Matrix Metalloproteinase-2 in a Nuclear Factor-κB-Dependent Manner

Overexpression of HMGA2 Promotes Metastasis and Impacts Survival of Colorectal Cancers.

HMGN1 loss sensitizes lung cancer cells to chemotherapy

Predictive Biomarkers and Personalized Medicine Overexpression of HMGA 2 Promotes Metastasis and Impacts Survival of Colorectal Cancers

Expression and significance of HMGN5 in lung cancer cell

High Mobility Group A 1 Expression as a Poor Prognostic Marker Associated with Tumor Invasiveness in Gastric Cancer

EXPRESSION OF HMGA2 AND ITS RELATIONSHIP WITH CELL PROLIFERATION IN NON-SMALL CELL LUNG CANCER

[Expression and Clinical Significance of HMGA2 in Renal Carcinoma].

Oncogenic Role of HMGB1 as An Alarming in Robust Prediction of Immunotherapy Response in Colorectal Cancer